Press

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Mar 21 • 4 min read

Psyence Group Inc. (CSE:PSYG / OTCQB: PSYGE), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that its newly incorporated wholly owned Australian subsidiary, Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based,…

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Mar 21 • 7 min read

Wesana Health Holdings Inc. (CSE: WESA / OTCQB: WSNAF), a data-driven life sciences company, today announced that the Company has entered into a definitive asset purchase agreement dated March 20 2023 (the “Asset Purchase Agreement”) with Lucy Scientific Discovery Inc. (NASDAQ:LSDI) for the sale by Wesana Health Inc. (“WHI”), a subsidiary of the Company, of its SANA-013 intellectual property…

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

Mar 21 • 3 min read

Diamond Therapeutics Inc., a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce the FDA’s authorization of the IND application submitted by collaborator Dr. Peter Hendricks. The FDA’s authorization allows Dr. Hendricks to proceed with a human clinical trial evaluating the effects of repeat low…

Algernon Pharmaceuticals Announces Launch of Rights Offering

Mar 21 • 7 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”). The Company will be offering 9,666,988 rights (the “Rights”) to holders (the “Shareholders”) of its Class A common shares (the “Shares”)…

First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder

Mar 21 • 4 min read

Clairvoyant Therapeutics is pleased to announce that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first dose of the drug along with Motivational Enhancement Therapy (MET). CLA-PSY-201 is the company’s placebo-controlled, randomized, multi-site phase 2b trial exploring psilocybin therapy as a treatment for alcohol use disorder (AUD). The first CLA-PSY-201…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441